VR Logo

ALX Oncology Holdings Inc. (ALXO) download report


Healthcare | Biotechnology & Pharma Research

ALX Oncology Holdings Inc. (ALXO) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer.

IPO Date: 17-Jul-2020

Independent Exec. Chairman: Dr. Corey S. Goodman Ph.D.

Founder, Pres, CEO & Director: Dr. Jaume Pons Ph.D.

Listing: NASDAQ: ALXO

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.alxoncology.com

Key Facts

Market cap: $334.80 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-93.81 Mln

Cash: $316.60 Mln

Total Debt: $1.03 Mln

Insider's Holding: 13.46%

Liquidity: Low

52 Week range: $5.82 - 81.19

Shares outstanding: 40,680,900

Stock Performance

Time Period ALX Oncology Holdings (ALXO) S&P BSE Sensex S&P Small-Cap 600
YTD-57.65-7.86-19.66
1 month19.75-3.75-9.44
3 months-51.51-10.80-13.14
1 Year-83.721.50-17.78
3 Years--10.755.52
5 Years--11.435.61
10 Years--11.849.50
As on 06-Jul-2022
Year ALX Oncology Holdings (ALXO) S&P Small-Cap 600 S&P BSE Sensex
2021-75.0725.2721.99